Commerzbank Aktiengesellschaft FI Purchases Shares of 9,916 Moderna, Inc. $MRNA

Commerzbank Aktiengesellschaft FI purchased a new position in shares of Moderna, Inc. (NASDAQ:MRNA) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 9,916 shares of the company’s stock, valued at approximately $504,000.

Other institutional investors have also recently modified their holdings of the company. AQR Capital Management LLC bought a new stake in Moderna in the 1st quarter worth approximately $415,000. NewEdge Advisors LLC grew its position in Moderna by 732.7% during the first quarter. NewEdge Advisors LLC now owns 11,575 shares of the company’s stock valued at $328,000 after acquiring an additional 10,185 shares during the last quarter. United Services Automobile Association purchased a new position in shares of Moderna during the first quarter worth approximately $230,000. Focus Partners Wealth raised its stake in shares of Moderna by 58.7% during the first quarter. Focus Partners Wealth now owns 23,547 shares of the company’s stock worth $668,000 after acquiring an additional 8,706 shares in the last quarter. Finally, American Century Companies Inc. lifted its holdings in shares of Moderna by 5.2% in the 2nd quarter. American Century Companies Inc. now owns 48,859 shares of the company’s stock worth $1,348,000 after acquiring an additional 2,410 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors.

Moderna Stock Performance

Shares of NASDAQ:MRNA opened at $58.07 on Thursday. The company has a current ratio of 2.41, a quick ratio of 2.35 and a debt-to-equity ratio of 0.08. The company has a 50-day moving average price of $58.28 and a 200-day moving average price of $51.57. The company has a market cap of $23.04 billion, a price-to-earnings ratio of -7.13 and a beta of 0.94. Moderna, Inc. has a 12 month low of $22.28 and a 12 month high of $85.60.

Moderna (NASDAQ:MRNA) last posted its earnings results on Friday, May 1st. The company reported ($3.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.02) by ($0.38). Moderna had a negative return on equity of 26.64% and a negative net margin of 143.55%.The business had revenue of $389.00 million during the quarter, compared to the consensus estimate of $236.37 million. During the same period in the previous year, the business earned ($2.52) earnings per share. The firm’s revenue for the quarter was up 260.2% compared to the same quarter last year. As a group, equities analysts anticipate that Moderna, Inc. will post -6.41 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on MRNA. Piper Sandler upped their price objective on shares of Moderna from $69.00 to $77.00 and gave the company an “overweight” rating in a research note on Friday, June 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Moderna in a research note on Friday, June 12th. Barclays upped their price target on shares of Moderna from $25.00 to $48.00 and gave the company an “equal weight” rating in a research report on Thursday, April 2nd. Bank of America raised their price objective on Moderna from $34.00 to $38.00 and gave the company an “underperform” rating in a research note on Tuesday, July 7th. Finally, Wolfe Research reiterated an “underperform” rating and issued a $25.00 price objective on shares of Moderna in a report on Monday. Two analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and five have assigned a Sell rating to the company. According to data from MarketBeat.com, Moderna has a consensus rating of “Reduce” and a consensus price target of $40.00.

Insiders Place Their Bets

In other Moderna news, President Stephen Hoge sold 53,336 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $51.37, for a total value of $2,739,870.32. Following the completion of the sale, the president owned 1,483,848 shares in the company, valued at approximately $76,225,271.76. This trade represents a 3.47% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Thyme Klinger sold 3,471 shares of Moderna stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $50.00, for a total value of $173,550.00. Following the completion of the sale, the insider owned 67,468 shares in the company, valued at approximately $3,373,400. This represents a 4.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 125,088 shares of company stock worth $6,193,713. Corporate insiders own 10.80% of the company’s stock.

Moderna Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.